Advertisement

Infection

, Volume 24, Issue 2, pp 156–158 | Cite as

Antibody response to measles vaccination in Turkish children

  • N. Kuyucu
  • Ü. Dogru
  • N. Akar
Brief Communication

Summary

In recent years, there has been a remarkable increase in measles cases among preschool and secondary school children in Turkey, as in many other countries. The seroconversion and coverage rates of measles vaccine should therefore be evaluated in order to obtain data that could be used to determine the vaccination policy for Turkey. Measles immunity status was studied by an enzyme-linked immunosorbent (ELISA) test determining the anti-measles IgG antibody levels. Measles specific IgG antibodies were found to be positive in 77.88% of the entire study group of 800 children aged 11 months to 12 years, while 21.25% had negative sera. Seven (0.87%) subjects had borderline results. The results of this study indicate the need to administer a second dose of measles vaccine, preferably at 18 months of age concomitant with other vaccines. This vaccination policy, together with an increase in the extent of immunization coverage, may help to achieve the World Health Organization's (WHO) target of the complete eradication of measles.

Keywords

Measle Immunization Coverage Measle Vaccine Measle Vaccination Vaccination Policy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Antikörperantwort auf Masernimpfung bei türkischen Kindern

Zusammenfassung

Masernfälle haben in den letzten Jahren bei Vorschul- und Schulkindern in der Türkei erheblich zugenommen. Diese Beobachtung wurde auch in anderen Ländern gemacht. Es ist daher nötig, Untersuchungen zur Serokonversion und Durchimpfung mit Masernimpfstoff durchzuführen, um Daten zu haben, die als Grundlage für die Impfstrategien in der Türkei verwendet werden können. Der Masern-Immunstatus wurde mittels enzymgebundenem Immunsorbent-Assay (ELISA) bestimmt. Die Messung der anti-Masern IgG-Antikörperspiegel ergab einen positiven Befund bei 77,88% der gesamten Gruppe von 800 Kindern im Alter von 11 Monaten bis 12 Jahren. 21,25% der Seren wurden als negativ beurteilt. Sieben Kinder (0,87%) hatten grenzwertige Ergebnisse. Die Daten der Studie sprechen dafür, vorzugsweise im Alter von 18 Monaten eine zweite Dosis Masernimpfstoff zu applizieren, wenn auch andere Impfungen erfolgen. Mit dieser Impfstrategie und einer besseren Durchimpfung könnte das Ziel der Weltgesundheitsorganisation (WHO), Masern völlig auszurotten, leichter erreicht werden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gershon, A. A. Measles virus. In:Mandell, G. L., Bennett, J. E., Dolin, R. (eds.): Principles and practice of infectious disease. Churchill Livingstone, New York 1995, pp. 1519–1526.Google Scholar
  2. 2.
    Chui, L. W. L., Marusyk, R. G., Pabst, H. F. Measles virus specific antibody in infants in a highly vaccinated society. J. Med. Virol. 33 (1991) 199–204.Google Scholar
  3. 3.
    Aaby, P., Clements, C. J. Measles immunization research: a review. Bull. OMS 67 (1989) 443–448.Google Scholar
  4. 4.
    Markowitz, L. E., Orenstein, W. A. Measles vaccines. Pediatr. Clin. North. Am. 37 (1990) 603–625.Google Scholar
  5. 5.
    Adcock, L. M., Bissey, J. D., Feigin, R. D. A new look at measles. Infect. Dis. Clin. North Am. 6 (1992) 133–148.Google Scholar
  6. 6.
    Markowitz, L. E., Preblud, S. R., Fine, P. E. M., Orenstein, W. A. Duration of live measles vaccine-induced immunity. Pediatr. Infect. Dis. J. 9 (1990) 101–110.Google Scholar
  7. 7.
    Christenson, B., Böttiger, M. Methods for screening the naturally acquired and vaccine-induced immunity to the measles virus. Biologicals 18 (1990) 207–211.Google Scholar
  8. 8.
    Cutts, F. T. Measles. World Health Organization, Geneva 1993.Google Scholar
  9. 9.
    Chen, R. T., Goldbaum, G. M., Wassilak, S. G. F., Markowitz, L. E., Orenstein, W. A. An explosive point-source measles outbreak in a highly vaccinated population. Am. J. Epidemiol. 129 (1989) 173–182.Google Scholar
  10. 10.
    Schlenker, T. L., Bain, C., Baughman, A. L., Hadler, S. C. Measles herd immunity. JAMA 267 (1992) 823–826.Google Scholar
  11. 11.
    Lerman, Y., Riskin-Mashiach, S., Cohen, D., Slepon, R., Shohat, T., Harari, H., Wiener, M., Danon, Y. L. Immunity to measles in young adults in Israel. Infection 21 (1993) 154–157.Google Scholar
  12. 12.
    Albrecht, P., Ennis, F. A., Saltzman, E. J., Krugman, S. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J. Pediatr. 91 (1977) 715–718.Google Scholar
  13. 13.
    Shasby, D. M., Shope, T. C., Downs, H. Epidemic measles in a highly vaccinated population. N. Engl. J. Med. 296 (1977) 585–589.Google Scholar
  14. 14.
    Yeager, A. S., Davis, J. H., Ross, L. A., Harvey, B. Measles immunization: successes and failures. JAMA 237 (1987) 347–351.Google Scholar
  15. 15.
    Ceyhan, M., Kanra, G., Vargel, S., Isikcelik, Y. The evaluation of vaccination against measles at nine months of age. Turkish J. Pediatr. 343 (1992) 127–133.Google Scholar

Copyright information

© MMV Medizin Verlag GmbH München 1996

Authors and Affiliations

  • N. Kuyucu
    • 1
  • Ü. Dogru
    • 2
  • N. Akar
    • 3
  1. 1.Dr. Sami Ulus Children's HospitalÖncebeci, Ankara
  2. 2.Dept of Pediatrics, Infectious Disease UnitAnkara University Faculty of MedicineAnkaraTurkey
  3. 3.Dept. of Pediatrics, Molecular Pathology UnitAnkara University Faculty of MedicineAnkaraTurkey

Personalised recommendations